Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
ACRS Stock Chart & Stats
$3.10
-$0.03(-1.20%)
At close: 4:00 PM EST
$3.10
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$1.05 - $4.89
Previous CloseN/A
Volume227.82K
Average Volume (3M)1.11M
Market Cap
$366.61M
Enterprise Value$321.28M
Total Cash (Recent Filing)$90.75M
Total Debt (Recent Filing)$2.12M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 12, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding120,595,190
10 Day Avg. Volume1,094,755
30 Day Avg. Volume1,106,653
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue41.05
Enterprise Value/Gross Profit56.02
Enterprise Value/Ebitda-4.69
Forecast
1Y Price Target
$11.33Price Target Upside265.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$5.97M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPlacebo-controlled Phase 1b testing of ATI-052 in asthma offers a clear pathway to demonstrate safety, biomarker changes, and lung function benefits that could validate the asset's best-in-class potential.
Differentiated Mechanism And PotencyATI-2138's dual targeting of ITK and JAK3 and higher potency versus a competing ITK inhibitor suggest a differentiated efficacy profile that could expand use across multiple inflammatory and autoimmune indications.
Pipeline Breadth And Strategic SignalsA portfolio that includes advancing small molecules and biologics, combined with demonstrated long half-life and tolerability for lead assets and recent industry acquisitions of long-acting immune therapies, creates multiple upcoming clinical readouts and strategic validation points.
Bears Say
Clinical Outcome RiskNegative clinical results or delays for bosakitug or other pipeline candidates could materially reduce expected product value and damp investor confidence.
Regulatory And Financial RiskFailure to secure approval for key programs, along with potential long-term dilution and weaker-than-expected sales, could weigh on future revenue and share performance.
Translational RiskEfficacy signals based primarily on animal models leave uncertainty about human benefit until supportive human trial data are available.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.05 and its highest was $4.89 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $366.61M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 67 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.015.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 120,595,190 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went down -5.438%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (265.48% Upside)
$11.33 (265.48% Upside)
Hedge Fund Trend
Increased
By 742.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.39%
12-Months-Change
Fundamentals
Return on Equity
-113.23%
Trailing 12-Months
Asset Growth
17.43%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$11.33
▲(265.48% Upside)
Technical Analysis
Ownership Overview
3.01% Insiders
8.69% Mutual Funds
29.42% Other Institutional Investors
46.30% Public Companies and
Individual Investors